基于树突状细胞的免疫疗法。
Dendritic cell-based immunotherapy.
作者信息
Sabado Rachel L, Balan Sreekumar, Bhardwaj Nina
机构信息
The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York City, NY 10029, USA.
出版信息
Cell Res. 2017 Jan;27(1):74-95. doi: 10.1038/cr.2016.157. Epub 2016 Dec 27.
Abstract
Immunotherapy using dendritic cell (DC)-based vaccination is an approved approach for harnessing the potential of a patient's own immune system to eliminate tumor cells in metastatic hormone-refractory cancer. Overall, although many DC vaccines have been tested in the clinic and proven to be immunogenic, and in some cases associated with clinical outcome, there remains no consensus on how to manufacture DC vaccines. In this review we will discuss what has been learned thus far about human DC biology from clinical studies, and how current approaches to apply DC vaccines in the clinic could be improved to enhance anti-tumor immunity.
摘要
使用基于树突状细胞（DC）的疫苗进行免疫治疗是一种已获批准的方法，可利用患者自身免疫系统的潜力来消除转移性激素难治性癌症中的肿瘤细胞。总体而言，尽管许多DC疫苗已在临床上进行了测试并被证明具有免疫原性，并且在某些情况下与临床结果相关，但在如何生产DC疫苗方面仍未达成共识。在这篇综述中，我们将讨论到目前为止从临床研究中学到的关于人类DC生物学的知识，以及如何改进目前在临床上应用DC疫苗的方法以增强抗肿瘤免疫力。
相似文献
1
Dendritic cell-based immunotherapy.基于树突状细胞的免疫疗法。
Cell Res. 2017 Jan;27(1):74-95. doi: 10.1038/cr.2016.157. Epub 2016 Dec 27.
2
Eliciting cytotoxic T lymphocytes against human laryngeal cancer-derived antigens: evaluation of dendritic cells pulsed with a heat-treated tumor lysate and other antigen-loading strategies for dendritic-cell-based vaccination.诱导针对人喉癌衍生抗原的细胞毒性T淋巴细胞：对用热处理肿瘤裂解物脉冲的树突状细胞及基于树突状细胞疫苗接种的其他抗原加载策略的评估
J Exp Clin Cancer Res. 2016 Jan 22;35:18. doi: 10.1186/s13046-016-0295-1.
3
Dendritic cell vaccines for cancer immunotherapy.用于癌症免疫治疗的树突状细胞疫苗。
Annu Rev Med. 1999;50:507-29. doi: 10.1146/annurev.med.50.1.507.
4
The use of dendritic cells for peptide-based vaccination in cancer immunotherapy.树突状细胞在癌症免疫治疗中用于基于肽的疫苗接种。
Methods Mol Biol. 2014;1139:479-503. doi: 10.1007/978-1-4939-0345-0_37.
5
Dendritic cells in cancer immunotherapy.癌症免疫治疗中的树突状细胞。
Eur J Immunol. 2010 Aug;40(8):2123-30. doi: 10.1002/eji.201040630.
6
Dendritic Cell-Based Immunotherapy: State of the Art and Beyond.基于树突状细胞的免疫疗法：现状与展望。
Clin Cancer Res. 2016 Apr 15;22(8):1897-906. doi: 10.1158/1078-0432.CCR-15-1399.
7
Current methods for loading dendritic cells with tumor antigen for the induction of antitumor immunity.目前用于用肿瘤抗原负载树突状细胞以诱导抗肿瘤免疫的方法。
J Immunother. 2002 Jul-Aug;25(4):289-303. doi: 10.1097/00002371-200207000-00001.
8
Dendritic-cell immunotherapy: from ex vivo loading to in vivo targeting.树突状细胞免疫疗法：从体外负载到体内靶向
Nat Rev Immunol. 2007 Oct;7(10):790-802. doi: 10.1038/nri2173.
9
Dendritic cell preparation for immunotherapeutic interventions.树突状细胞制备用于免疫治疗干预。
Immunotherapy. 2009 Mar;1(2):289-302. doi: 10.2217/1750743X.1.2.289.
10
Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma.树突状细胞作为抗肿瘤治疗性疫苗及其在肝细胞癌治疗中的作用。
Cell Mol Immunol. 2006 Jun;3(3):197-203.
引用本文的文献
1
Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy.用于联合肿瘤免疫治疗的序贯给药系统的工程策略。
Acta Pharm Sin B. 2025 Aug;15(8):3951-3977. doi: 10.1016/j.apsb.2025.05.039. Epub 2025 Jun 6.
2
Prospects and Challenges of Lung Cancer Vaccines.肺癌疫苗的前景与挑战
Vaccines (Basel). 2025 Aug 5;13(8):836. doi: 10.3390/vaccines13080836.
3
Heat up, silence on: IDO1 gene silencing in THP-1-derived dendritic cells triggered by magnetic hyperthermia.升温，沉默开启：磁热疗法触发THP-1来源的树突状细胞中IDO1基因沉默
Cancer Immunol Immunother. 2025 Aug 23;74(9):292. doi: 10.1007/s00262-025-04148-3.
4
Refining Dendritic Cell-Based Cancer Vaccines: Subset Targeting, Translational Barriers, and Emerging Strategies.优化基于树突状细胞的癌症疫苗：亚群靶向、转化障碍及新兴策略
J Microbiol Biotechnol. 2025 Aug 12;35:e2506021. doi: 10.4014/jmb.2506.06021.
5
Dual-mode immunotherapy: ultrasound responsive zinc-based nano-contract agents synergistically activate the GAS-STING pathway for enhanced tumor sono-metalloimmunotherapy.双模式免疫疗法：超声响应性锌基纳米收缩剂协同激活GAS-STING通路以增强肿瘤超声金属免疫疗法。
Ultrason Sonochem. 2025 Aug 4;120:107494. doi: 10.1016/j.ultsonch.2025.107494.
6
Research and Clinical Progress of Therapeutic Tumor Vaccines.治疗性肿瘤疫苗的研究与临床进展
Vaccines (Basel). 2025 Jun 23;13(7):672. doi: 10.3390/vaccines13070672.
7
Eliciting antitumor immunity via therapeutic cancer vaccines.通过治疗性癌症疫苗激发抗肿瘤免疫力。
Cell Mol Immunol. 2025 Jul 9. doi: 10.1038/s41423-025-01316-4.
8
Lung cancer vaccine strategies: exploring the spectrum from traditional to RNA-based platforms.肺癌疫苗策略：探索从传统平台到基于RNA平台的范围
Front Bioeng Biotechnol. 2025 Jun 23;13:1617352. doi: 10.3389/fbioe.2025.1617352. eCollection 2025.
9
Metabotropic glutamate receptor 4-mediated glutamatfergic signaling reshapes the tumor microenvironment by regulating dendritic cell maturation.代谢型谷氨酸受体4介导的谷氨酸能信号通过调节树突状细胞成熟来重塑肿瘤微环境。
Nat Commun. 2025 Jul 1;16(1):5874. doi: 10.1038/s41467-025-60922-y.
10
deletion enhances cross-priming of CD8+ T cells by tumor-infiltrating CD11b+ dendritic cells.缺失增强了肿瘤浸润性CD11b+树突状细胞对CD8+T细胞的交叉呈递。
J Immunother Cancer. 2025 Jun 23;13(6):e011815. doi: 10.1136/jitc-2025-011815.
本文引用的文献
1
Targeting CLEC9A delivers antigen to human CD141 DC for CD4 and CD8T cell recognition.靶向 CLEC9A 将抗原递呈给人 CD141 DC 以识别 CD4 和 CD8T 细胞。
JCI Insight. 2016 May 19;1(7):e87102. doi: 10.1172/jci.insight.87102.
2
Critical Role for CD103(+)/CD141(+) Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in Melanoma.携带CCR7的CD103(+)/CD141(+)树突状细胞在黑色素瘤肿瘤抗原转运及T细胞免疫启动中的关键作用
Cancer Cell. 2016 Aug 8;30(2):324-336. doi: 10.1016/j.ccell.2016.06.003. Epub 2016 Jul 14.
3
Systemic RNA delivery to dendritic cells exploits antiviral defence for cancer immunotherapy.系统性 RNA 递送至树突状细胞利用抗病毒防御机制进行癌症免疫治疗。
Nature. 2016 Jun 16;534(7607):396-401. doi: 10.1038/nature18300. Epub 2016 Jun 1.
4
Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition.肿瘤部位CD103(+)树突状细胞祖细胞的扩增与激活增强了肿瘤对治疗性PD-L1和BRAF抑制的反应。
Immunity. 2016 Apr 19;44(4):924-38. doi: 10.1016/j.immuni.2016.03.012.
5
CD4 Receptor is a Key Determinant of Divergent HIV-1 Sensing by Plasmacytoid Dendritic Cells.CD4受体是浆细胞样树突状细胞对不同HIV-1感知的关键决定因素。
PLoS Pathog. 2016 Apr 15;12(4):e1005553. doi: 10.1371/journal.ppat.1005553. eCollection 2016 Apr.
6
The Dendritic Cell Synapse: A Life Dedicated to T Cell Activation.树突状细胞突触：致力于T细胞激活的一生。
Front Immunol. 2016 Mar 7;7:70. doi: 10.3389/fimmu.2016.00070. eCollection 2016.
7
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.转移性黑色素瘤中抗PD-1治疗反应的基因组和转录组特征
Cell. 2016 Mar 24;165(1):35-44. doi: 10.1016/j.cell.2016.02.065. Epub 2016 Mar 17.
8
Visualization of immediate immune responses to pioneer metastatic cells in the lung.肺部对先驱转移性细胞的即时免疫反应的可视化。
Nature. 2016 Mar 24;531(7595):513-7. doi: 10.1038/nature16985. Epub 2016 Mar 16.
9
Comparative genomics analysis of mononuclear phagocyte subsets confirms homology between lymphoid tissue-resident and dermal XCR1(+) DCs in mouse and human and distinguishes them from Langerhans cells.单核吞噬细胞亚群的比较基因组学分析证实了小鼠和人类淋巴组织驻留性与真皮XCR1(+)树突状细胞（DCs）之间的同源性，并将它们与朗格汉斯细胞区分开来。
J Immunol Methods. 2016 May;432:35-49. doi: 10.1016/j.jim.2016.02.023. Epub 2016 Mar 7.
10
First oncolytic virus approved for melanoma immunotherapy.首个获批用于黑色素瘤免疫治疗的溶瘤病毒。
Oncoimmunology. 2015 Dec 8;5(1):e1115641. doi: 10.1080/2162402X.2015.1115641. eCollection 2016.
Zotero 插件